DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Rifalazil is an investigational drug.
There have been 3 clinical trials for Rifalazil. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2005.
The most common disease conditions in clinical trials are Vascular Diseases, Peripheral Vascular Diseases, and Peripheral Arterial Disease. The leading clinical trial sponsors are ActivBiotics, ActivBiotics Pharma, LLC, and [disabled in preview].
Recent Clinical Trials for Rifalazil
|Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women||ActivBiotics Pharma, LLC||Phase 2|
|RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease||ActivBiotics||Phase 2|
|PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients||ActivBiotics||Phase 3|